Integrative genomic profiling of human prostate cancer.

[1]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[2]  R. T. Curtis,et al.  A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. , 1997, Genomics.

[3]  E. Lander,et al.  Gene expression correlates of clinical prostate cancer behavior. , 2002, Cancer cell.

[4]  Yudong D. He,et al.  A Gene-Expression Signature as a Predictor of Survival in Breast Cancer , 2002 .

[5]  P. Febbo,et al.  Use of expression analysis to predict outcome after radical prostatectomy. , 2003, The Journal of urology.

[6]  Cheng Li,et al.  Genome-wide loss of heterozygosity analysis from laser capture microdissected prostate cancer using single nucleotide polymorphic allele (SNP) arrays and a novel bioinformatics platform dChipSNP. , 2003, Cancer research.

[7]  J. Klein,et al.  Positive and Negative Roles of p85α and p85β Regulatory Subunits of Phosphoinositide 3-Kinase in Insulin Signaling* , 2003, Journal of Biological Chemistry.

[8]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[9]  Shih-Ming Huang,et al.  Analysis of two CBP (cAMP-response-element-binding protein-binding protein) interacting sites in GRIP1 (glucocorticoid-receptor-interacting protein), and their importance for the function of GRIP1. , 2004, The Biochemical journal.

[10]  R. Vessella,et al.  Molecular determinants of resistance to antiandrogen therapy , 2004, Nature Medicine.

[11]  R. Tibshirani,et al.  Gene expression profiling identifies clinically relevant subtypes of prostate cancer. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[12]  A. Newton,et al.  PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. , 2005, Molecular cell.

[13]  M. Cooperberg,et al.  The changing face of prostate cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Tchinda,et al.  Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer , 2005, Science.

[15]  Ronald W. Davis,et al.  Allele quantification using molecular inversion probes (MIP) , 2005, Nucleic acids research.

[16]  T. Golub,et al.  Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma , 2005, Nature.

[17]  Anna Frolov,et al.  Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. , 2005, Cancer research.

[18]  T. Golub,et al.  Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. , 2006, Cancer cell.

[19]  J. Tchinda,et al.  TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. , 2006, Cancer research.

[20]  Jin-Tang Dong.  Prevalent mutations in prostate cancer , 2006, Journal of cellular biochemistry.

[21]  S. Dhanasekaran,et al.  Integrative analysis of genomic aberrations associated with prostate cancer progression. , 2007, Cancer research.

[22]  Derek Y. Chiang,et al.  Characterizing the cancer genome in lung adenocarcinoma , 2007, Nature.

[23]  A. Banham,et al.  FOXP1: a potential therapeutic target in cancer , 2007, Expert opinion on therapeutic targets.

[24]  J. Brooks,et al.  Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. , 2007, Cancer research.

[25]  A. Ziaee,et al.  Role of PTEN gene in progression of prostate cancer. , 2007, Urology journal.

[26]  E. Birney,et al.  Patterns of somatic mutation in human cancer genomes , 2007, Nature.

[27]  S. Pfaff.  Developmental neuroscience: Hox and Fox , 2008, Nature.

[28]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[29]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[30]  A. Banham,et al.  FOXP1 abnormalities in lymphoma: translocation breakpoint mapping reveals insights into deregulated transcriptional control , 2008, Modern Pathology.

[31]  T. H. van der Kwast,et al.  Truncated ETV1, fused to novel tissue-specific genes, and full-length ETV1 in prostate cancer. , 2008, Cancer research.

[32]  R. Shah,et al.  Role of the TMPRSS2-ERG gene fusion in prostate cancer. , 2008, Neoplasia.

[33]  P. Kantoff,et al.  Testing a Multigene Signature of Prostate Cancer Death in the Swedish Watchful Waiting Cohort , 2008, Cancer Epidemiology Biomarkers & Prevention.

[34]  P. Nelson,et al.  A causal role for ERG in neoplastic transformation of prostate epithelium , 2008, Proceedings of the National Academy of Sciences.

[35]  P. Kantoff,et al.  Nine-Gene Molecular Signature Is Not Associated with Prostate Cancer Death in a Watchful Waiting Cohort , 2008, Cancer Epidemiology Biomarkers & Prevention.

[36]  G. Parmigiani,et al.  Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.

[37]  Brian H. Dunford-Shore,et al.  Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.

[38]  C. Sander,et al.  Functional Copy-Number Alterations in Cancer , 2008, PloS one.

[39]  FoxP1: conducting the Hox symphony in spinal motor neurons , 2008, Nature Neuroscience.

[40]  D. Ghosh,et al.  Genomic outlier profile analysis: mixture models, null hypotheses, and nonparametric estimation. , 2008, Biostatistics.

[41]  B. Peters,et al.  Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation. , 2009, Cancer cell.

[42]  Lin Lin,et al.  Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate. , 2009, Cancer cell.

[43]  H. Scher,et al.  Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer , 2009, Science.

[44]  Pier Paolo Pandolfi,et al.  Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate , 2009, Nature Genetics.

[45]  M. Teitell,et al.  ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells , 2009, Proceedings of the National Academy of Sciences.

[46]  Hui Wang,et al.  RYBP stabilizes p53 by modulating MDM2 , 2009, EMBO reports.

[47]  R. Shah,et al.  Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression , 2009, Modern Pathology.

[48]  P. Pandolfi,et al.  Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. , 2009, Cancer cell.

[49]  P. Grozdanov,et al.  SHQ1 is required prior to NAF1 for assembly of H/ACA small nucleolar and telomerase RNPs. , 2009, RNA.

[50]  Chris Sander,et al.  An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors , 2009, Oncogene.

[51]  C. Sander,et al.  Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis , 2009, Nature Genetics.

[52]  M. Gerstein,et al.  Distinct genomic aberrations associated with ERG rearranged prostate cancer , 2009, Genes, chromosomes & cancer.

[53]  Mahavir Singh,et al.  Structure and Functional Studies of the CS Domain of the Essential H/ACA Ribonucleoparticle Assembly Protein SHQ1* , 2009, Journal of Biological Chemistry.

[54]  Derek Y. Chiang,et al.  The landscape of somatic copy-number alteration across human cancers , 2010, Nature.

[55]  W. Gerald,et al.  Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer , 2010, British Journal of Cancer.

[56]  E. Birney,et al.  A small cell lung cancer genome reports complex tobacco exposure signatures , 2009, Nature.

[57]  Tom Royce,et al.  A comprehensive catalogue of somatic mutations from a human cancer genome , 2010, Nature.